Tg Therapeutics (TGTX) Accumulated Expenses (2010 - 2026)

Tg Therapeutics' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $18.7 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 263.29% year-over-year to $18.7 million; the TTM figure through Mar 2026 stood at $18.7 million (up 263.29% YoY), while the FY2025 annual figure was $21.8 million, up 43.89% from the prior year.
• Accumulated Expenses was $18.7 million for Q1 2026 at Tg Therapeutics, down from $21.8 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $21.8 million in Q4 2025 to a low of $1.6 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $9.1 million across 5 years, with a median of $8.3 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Accumulated Expenses sank 66.57% in 2022, then soared 263.29% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $8.4 million in 2022, then soared by 44.35% to $12.2 million in 2023, then grew by 24.75% to $15.2 million in 2024, then jumped by 43.89% to $21.8 million in 2025, then slipped by 14.62% to $18.7 million in 2026.
• The last three Accumulated Expenses figures came in at $18.7 million (Q1 2026), $21.8 million (Q4 2025), and $15.0 million (Q3 2025), per Business Quant data.